# Instil Bio

TIL platforms — optimised expansion.

Source: https://en.bioecon.ru/companies/instil-bio/
Updated: 2026-06-24

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Founded | August 2018 | https://www.sec.gov/Archives/edgar/data/1789769/000119312521060613/d138592ds1.htm |
| Headcount | 17 employees (as of December 31, 2025) | https://www.sec.gov/Archives/edgar/data/1789769/000178976925000017/til-20241231.htm, https://www.sec.gov/Archives/edgar/data/1789769/000178976926000034/instilbioinc10-k2025woexs.pdf |
| Revenue | No revenue generated from product sales to date | https://www.globenewswire.com/news-release/2023/08/14/2724234/0/en/Instil-Bio-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html, https://www.sec.gov/Archives/edgar/data/1789769/000178976925000017/til-20241231.htm |
| Production site | Tarzana, California (owned, leased to AstraZeneca); Alderley Park, United Kingdom (leased); Thousand Oaks, California (leased) | https://www.sec.gov/Archives/edgar/data/1789769/000178976925000017/til-20241231.htm, https://www.sec.gov/Archives/edgar/data/1789769/000178976926000034/instilbioinc10-k2025woexs.pdf |
| Funding | Raised $380.1 million in net proceeds from inception through 2021; cash, cash equivalents, restricted cash, and marketable securities were $69.9 million as of June 30, 2026 | https://www.sec.gov/Archives/edgar/data/1789769/000119312521060613/d138592ds1.htm, https://www.sec.gov/Archives/edgar/data/1789769/000178976926000034/instilbioinc10-k2025woexs.pdf, https://www.sec.gov/Archives/edgar/data/1789769/000178976926000044/q1-26er.htm, https://www.sec.gov/Archives/edgar/data/1789769/000178976926000055/q2-26er.htm |
| Capacity | No current commercial-scale capacity; focused on research and potential early-stage trials | https://koalagains.com/stocks/NASDAQ/TIL/future-performance |

Independent sources: globenewswire.com, koalagains.com, sec.gov

## Technologies

- [TIL therapy (tumor-infiltrating lymphocytes)](https://en.bioecon.ru/technology/til-therapy/)